Description
BAY-1816032 is an inhibitor of budding uninhibited by benzimidazoles 1 kinase (BUB1). When used alone or in combination with taxanes, ATR, and PARP inhibitors, BAY-1816032 inhibits tumor growth in human triple-negative breast xenograft models in vivo to varying degrees. Treatment with BAY-1816032 in combination with both paclitaxel or olaparib resulted in a further reduction in tumor size compared to the monotherapies.